Moderna (MRNA): Why Software Is Now Part of the Cancer Drug [Q3 2026]
10m | Nov 6, 2026Moderna (MRNA) wired out a $950M patent settlement in Q3 2026 yet still expanded its cash pile to $8B while locking proprietary software into its first cancer drug filing. đ§Ź
In ~10 minutes:
- Why $1.37B in uncollected vaccine IOUs masked Q3 operating cash burn
- Raising $2.6B in 0% convertible debt to fund the oncology pivot
- How proprietary antigen-selection software becomes part of the melanoma BLA
- Abruptly halting the second norovirus trial cohort to trim $200M in R&D
- Missing the spring pharmacy contracting window for the new flu shot
While multi-year international government vaccine contracts drove a 29% YoY revenue beat and a full-year guidance hike, the real story is Moderna's transition into a personalized oncology powerhouse. We unpack the bioinformatics breakthrough that allowed Moderna to scale its neoantigen training dataset from just 7 willing patients in Phase 2 to standard whole-blood draws in Phase 3.
Company: Moderna, Inc. (MRNA) | Q3 FY2026
AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.
